AbbVie scoops up option to license Harpoon's BCMA drug for $50M upfront as biotech partner preps PhI/II trial
AbbVie is arming itself with another set of bow and arrows to shoot at BCMA in multiple myeloma — and this time it has turned to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
